Mesothelioma | Mesothelioma

Patients Taking NexavarBased on the current, approved package insert for the treatment of patients with advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed.

Incidence of bleeding regardless of causality was 15% for Nexavar vs.

8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs.

0.4% for placebo.

Most common treatment-emergent adverse events with Nexavar were diarrhea, rash/desquamation, fatigue, hand-foot skin reaction, alopecia, and nausea.

Grade 3/4 adverse events were 38% for Nexavar vs.

28% for placebo.

Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding.

In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.For U.S.

Nexavar prescribing information, visit http://www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).Bayer/Onyx Co-DevelopmentNexavar is being co-developed by Bayer and Onyx.

The co-development collaboration calls for Onyx to fund 50 percent of the development a...

Read more...